High level expression, purification and characterization of recombinant CCR5 as a vaccine candidate against HIV

Protein Expression and Purification

Volumn 89, Issue 2, 2013, Pages 124-130

  Wu, Kongtian ^a,b   Xue, Xiaochang ^a   Li, Meng ^a   Qin, Xin ^a   Zhang, Cun ^a   Li, Weina ^a   Hao, Qiang ^a   Wang, Zenglu ^a   Liu, Qian ^a   Zhang, Wei ^a   Zhang, Yingqi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NONE   (China)

Author keywords

CCR5; Inclusion body; PADRE; Purification; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84876117362     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2013.03.008     Document Type: Article

References (28)

1. R. Rossi, M. Lichtner, A. De Rosa, I. Sauzullo, F. Mengoni, A.P. Massetti, C.M. Mastroianni, and V. Vullo In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells Clin. Exp. Immunol. 166 2011 184 190
2. M. Oppermann Chemokine receptor CCR5: insights into structure, function, and regulation Cell. Signal. 16 2004 1201 1210 (Pubitemid 39165449)
3. A.E. Proudfoot, S. Fritchley, F. Borlat, J.P. Shaw, F. Vilbois, C. Zwahlen, A. Trkola, D. Marchant, P.R. Clapham, and T.N. Wells The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity J. Biol. Chem. 276 2001 10620 10626 (Pubitemid 38089230)
4. C.J. Raport, J. Gosling, V.L. Schweickart, P.W. Gray, and I.F. Charo Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha J. Biol. Chem. 271 1996 17161 17166 (Pubitemid 26244268)
5. S. Struyf, P. Menten, J.P. Lenaerts, W. Put, A. D'Haese, E. De Clercq, D. Schols, P. Proost, and J. Van Damme Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils Eur. J. Immunol. 31 2001 2170 2178 (Pubitemid 32640734)
6. + cells is mediated by the chemokine receptor CC-CKR-5 Nature 381 1996 667 673 (Pubitemid 26197680)
7. G. Pollakis, and W.A. Paxton Use of (alternative) coreceptors for HIV entry Curr. Opin. HIV AIDS 7 2012 440 449
8. B. Chackerian, L. Briglio, P.S. Albert, D.R. Lowy, and J.T. Schiller Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus J. Virol. 78 2004 4037 4047 (Pubitemid 38437210)
9. Z.L. Brumme, J. Goodrich, H.B. Mayer, C.J. Brumme, B.M. Henrick, B. Wynhoven, J.J. Asselin, P.K. Cheung, R.S. Hogg, J.S. Montaner, and P.R. Harrigan Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals J. Infect. Dis. 192 2005 466 474 (Pubitemid 41023125)
10. G.J. Moyle, A. Wildfire, S. Mandalia, H. Mayer, J. Goodrich, J. Whitcomb, and B.G. Gazzard Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection J. Infect. Dis. 191 2005 866 872 (Pubitemid 40349800)
11. M. Dean, M. Carrington, C. Winkler, G.A. Huttley, M.W. Smith, R. Allikmets, J.J. Goedert, S.P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, and S.J. O'Brien Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, multicenter AIDS cohort study, multicenter hemophilia cohort study, San Francisco City Cohort, ALIVE study Science 273 1996 1856 1862
12. Y. Huang, W.A. Paxton, S.M. Wolinsky, A.U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, K. Kunstman, D. Erickson, E. Dragon, N.R. Landau, J. Phair, D.D. Ho, and R.A. Koup The role of a mutant CCR5 allele in HIV-1 transmission and disease progression Nat. Med. 2 1996 1240 1243 (Pubitemid 26375409)
13. J.C. Tilton, and R.W. Doms Entry inhibitors in the treatment of HIV-1 infection Antiviral Res. 85 2010 91 100
14. J.M. Farber, and E.A. Berger HIV's response to a CCR5 inhibitor: I'd rather tighten than switch! Proc. Natl. Acad. Sci. USA 99 2002 1749 1751 (Pubitemid 34168960)
15. E. Poveda, R. Paredes, S. Moreno, J. Alcami, J. Cordoba, R. Delgado, F. Gutierrez, J.M. Llibre, M. Garcia Deltoro, J. Hernandez-Quero, F. Pulido, J.A. Iribarren, and F. Garcia Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists AIDS Rev. 14 2012 208 217
16. H.P. Schlecht, S. Schellhorn, B.J. Dezube, and J.M. Jacobson New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists Ther. Clin. Risk Manage. 4 2008 473 485 (Pubitemid 351712006)
17. K. Wu, X. Xue, Z. Wang, Z. Yan, J. Shi, W. Han, and Y. Zhang Construction, purification, and immunogenicity of recombinant cystein-cystein type chemokine receptor 5 vaccine Protein Expr. Purif. 49 2006 108 113 (Pubitemid 44294766)
18. X. Xue, Z. Wang, Z. Yan, J. Shi, W. Han, and Y. Zhang Production and purification of recombinant human BLyS mutant from inclusion bodies Protein Expr. Purif. 42 2005 194 199 (Pubitemid 40793411)
19. H. Choe, W. Li, P.L. Wright, N. Vasilieva, M. Venturi, C.C. Huang, C. Grundner, T. Dorfman, M.B. Zwick, L. Wang, E.S. Rosenberg, P.D. Kwong, D.R. Burton, J.E. Robinson, J.G. Sodroski, and M. Farzan Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120 Cell 114 2003 161 170 (Pubitemid 36936910)
20. A.M. de Roda Husman, R.P. van Rij, H. Blaak, S. Broersen, and H. Schuitemaker Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression J. Infect. Dis. 180 1999 1106 1115 (Pubitemid 30070193)
21. M. Westby, and E. van der Ryst CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on Antimicrob. Agents Chemother. 20 2010 179 192
22. P. Biswas, G. Tambussi, and A. Lazzarin Access denied? The status of co-receptor inhibition to counter HIV entry Expert Opin. Pharmacother. 8 2007 923 933 (Pubitemid 351227480)
23. J.M. Jacobson, J.P. Lalezari, M.A. Thompson, C.J. Fichtenbaum, M.S. Saag, B.S. Zingman, P. D'Ambrosio, N. Stambler, Y. Rotshteyn, A.J. Marozsan, P.J. Maddon, S.A. Morris, and W.C. Olson Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults Antimicrob. Agents Chemother. 54 2010 4137 4142
24. J.M. Jacobson, M.A. Thompson, J.P. Lalezari, M.S. Saag, B.S. Zingman, P. D'Ambrosio, N. Stambler, Y. Rotshteyn, A.J. Marozsan, P.J. Maddon, S.A. Morris, and W.C. Olson Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody J. Infect. Dis. 201 2010 1481 1487
25. L. Li, T. Sun, K. Yang, P. Zhang, W.Q. Jia, Monoclonal CCR5 antibody for treatment of people with HIV infection, Cochrane Database Syst. Rev. (2010) CD008439.
26. M.M. Caseiro, M. Nelson, R.S. Diaz, J. Gathe, J.L. de Andrade Neto, J. Slim, A. Solano, E.M. Netto, C. Mak, J. Shen, W. Greaves, L.M. Dunkle, R.A. Vilchez, and J. Zeinecker Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials J. Infect. 65 2012 326 335
27. P. McNicholas, R.A. Vilchez, W. Greaves, S. Kumar, C. Onyebuchi, T. Black, and J.M. Strizki Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc J. Clin. Virol. 55 2012 134 139
28. B. Savkovic, G. Symonds, and J.M. Murray Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc PloS One 7 2012 e38755